SCHEMBL430583

SCHEMBL430583

[O]c1ccccc1SCc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.63
KMT2A Q03164 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
PTPRC P08575 1/20 0.49
HSD17B10 Q99714 1/20 0.47
MEN1 O00255 1/20 0.46
HTT P42858 2/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
S100A4 P26447 1/20 0.43
GAA P10253 2/20 0.42
MAPT P10636 2/20 0.42
PKM P14618 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15953118 0.84 POLB (0.55) POLBKMT2AL3MBTL1PTPRCHSD17B10
SCHEMBL2124636 0.79 PTPRC (0.54) KMT2AL3MBTL1PTPRCMEN1MAPT
SCHEMBL6638095 0.78 POLB (0.59) POLBKMT2AL3MBTL1PTPRCHSD17B10
SCHEMBL10679407 0.78 POLB (0.64) POLBKMT2AL3MBTL1PTPRCHSD17B10
SCHEMBL3896275 0.77 POLB (1.00) POLBKMT2AL3MBTL1PTPRCHSD17B10
SCHEMBL4334230 0.76 POLB (0.61) POLBKMT2AL3MBTL1PTPRCHSD17B10
SCHEMBL6916799 0.76 POLB (0.61) POLBKMT2AL3MBTL1PTPRCHSD17B10
SCHEMBL2929900 0.76 POLB (0.61) POLBKMT2AL3MBTL1PTPRCHSD17B10
SCHEMBL8148885 0.76 POLB (0.61) POLBKMT2AL3MBTL1PTPRCHSD17B10
SCHEMBL6504974 0.76 POLB (0.61) POLBKMT2AL3MBTL1PTPRCHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160009639-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS INC (US) 2016-01-14 US claimed
US-9169201-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2015-10-27 US claimed
EP-2786985-A2 Antagonists of the glucagon receptor Metabasis Therapeutics, Inc. (US) 2014-10-08 EP claimed
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2014-05-15 US claimed
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor METABASIS THERAPEUTICS, INC. (US) 2012-08-23 US claimed
EP-2129654-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR Metabasis Therapeutics, Inc. (US) 2009-12-09 EP claimed
WO-2008098244-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2008-08-14 WO claimed
US-20240182463-A1 SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG SHIONOGI & CO., LTD. (JP) 2024-06-06 US disclosed
CN-117693500-A Carboxamide derivative and agricultural/horticultural plant disease control agent 组合化学工业株式会社 2024-03-12 CN disclosed
US-20230133149-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-05-04 US disclosed
US-20230126543-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-04-27 US disclosed
US-20230117695-A1 ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2023-04-20 US disclosed
CN-115485272-A PLXDC2 ligands 朗多生物制药股份有限公司 2022-12-16 CN disclosed
EP-1768973-A1 SUBSTITUTED QUINOLONES AiCuris GmbH & Co. KG (DE) 2007-04-04 EP disclosed
WO-2006008046-A1 SUBSTITUTED QUINOLONES AICURIS GMBH & CO. KG (DE) 2006-01-26 WO disclosed
EP-0678505-B1 Oximethers and fungicides containing them BASF AG (DE) 1997-06-04 EP disclosed
EP-0679636-A1 Oximethers and fungicides containing them BASF Aktiengesellschaft (DE) 1995-11-02 EP disclosed
EP-0678505-A1 Oximethers and fungicides containing them BASF AKTIENGESELLSCHAFT (DE) 1995-10-25 EP disclosed
US-5446067-A For treatment of crops, seeds, soils BASF AKTIENGESELLSCHAFT (DE) 1995-08-29 US disclosed
EP-0498188-A2 Oximethers and fungicides containing them BASF Aktiengesellschaft (DE) 1992-08-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009639-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 POLB 4502/4885KMT2A 4280/4885L3MBTL1 3991/4885
US-20230133149-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE CYP1A1, CYP2E1, ORC3 POLB 2783/4885KMT2A 1561/4885L3MBTL1 1128/4885
US-20240182463-A1 SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG PREP, UNG, DPP4 POLB 292/4885KMT2A 1980/4885L3MBTL1 2179/4885
US-20230117695-A1 ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE CDK7, CCNA1, CCR10 POLB 2111/4885KMT2A 958/4885L3MBTL1 65/4885
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 POLB 4502/4885KMT2A 4280/4885L3MBTL1 3991/4885
US-20230126543-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE CYP1A1, AOX1, CRY1 POLB 2422/4885KMT2A 1754/4885L3MBTL1 1312/4885
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor GLP1R, GCGR, GPR119 POLB 4502/4885KMT2A 4280/4885L3MBTL1 3991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.